AOD9604 (hGH Fragment 176-191)
฿1,200.00
- Mechanism: hGH C-terminal fragment 176–191; selective lipolytic activity without IGF-1 pathway involvement
- Format: Lyophilized powder, 5mg per vial, >99% purity by HPLC
- Included: Vial + Certificate of Analysis (HPLC + mass spectrum)
For research use only. Not for human or veterinary consumption. In-vitro laboratory use only.
Description
Product Specifications
| Peptide | AOD9604 (hGH Fragment 176–191) |
|---|---|
| Also known as | AOD-9604 • hGH Frag 176-191 |
| CAS Number | 221231-10-3 |
| Molecular Weight | 1,815.10 Da |
| Quantity per vial | 5mg |
| Format | Lyophilized powder (white to off-white) |
| Purity | >99% by HPLC |
| Peptide content | ≥90% net peptide (adjusted for water and counter-ions) |
| Verification method | External HPLC chromatography + mass spectrometry |
| Certificate of Analysis | Provided digitally with every shipment |
| Reconstitution | Sterile water for injection or bacteriostatic water |
| Storage — lyophilized | −20°C, sealed vial, away from moisture and light |
| Storage — in solution | −80°C; use within 30 days; avoid freeze-thaw cycles |
| Shelf life | 24 months from manufacture date (lyophilized, correct storage) |
| Intended use | In-vitro laboratory research only. Not for human or veterinary use. |
Research Background
AOD9604 is a synthetic peptide corresponding to amino acids 176–191 of human growth hormone (hGH), with the addition of a tyrosine residue at the N-terminus. It was developed at Monash University as a lipolytic fragment designed to isolate the fat-metabolizing activity of hGH while avoiding the insulin resistance and IGF-1-pathway effects associated with the full hGH molecule. Unlike intact hGH, AOD9604 does not activate the IGF-1 axis.
In-vitro studies using pre-adipocyte and adipocyte cell models have shown that AOD9604 stimulates lipolysis and inhibits lipogenesis through mechanisms that appear to involve beta-3 adrenergic receptor interaction and downstream cAMP signaling. Its selectivity for lipid metabolism pathways without IGF-1 involvement makes it a useful tool compound for separating the metabolic arms of growth hormone receptor pharmacology.
Research Applications
- Lipolysis stimulation and lipogenesis inhibition assays in 3T3-L1 and primary adipocyte cell models
- Beta-3 adrenergic receptor binding studies and downstream cAMP quantification
- Adipokine secretion profiling (leptin, adiponectin) under AOD9604 stimulation
- Comparative GH fragment activity: AOD9604 vs. full hGH vs. other C-terminal fragments
- IGF-1 pathway decoupling studies confirming absence of GH receptor-mediated IGF-1 signaling
- Lipid droplet morphology and triglyceride content analysis in cultured adipocytes
- Energy expenditure pathway gene expression profiling (UCP1, PPARγ, FABP4)
Reconstitution Protocol
Allow the vial to reach room temperature before opening. Reconstitute in sterile water for injection or bacteriostatic water at the required working concentration. Do not vortex; gently swirl or invert until fully dissolved. Filter through a 0.22 μm sterile membrane if required for cell-based assays. Aliquot into single-use volumes before freezing to eliminate repeated freeze-thaw exposure.
Storage and Stability
Store lyophilized vials at −20°C in the original sealed container, protected from moisture and light. Lyophilized material stays stable for up to 24 months from the manufacture date shown on the Certificate of Analysis. Reconstituted solutions should be stored at −80°C and used within 30 days. Avoid repeated freeze-thaw cycles, which degrade the peptide over time.
What’s Included
- 1 × AOD9604 lyophilized vial — 5mg
- Independent Certificate of Analysis (HPLC chromatogram + mass spectrum + batch data)
- Batch number and expiry date printed on vial label
- Discreet external packaging with no product name or branding on the exterior
Leave a Comment